Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Tsagkaris (Athens, Greece), E. Vrigkou (Athens, Greece), D. Konstantonis (Athens, Greece), F. Frantzeskaki (Athens, Greece), A. Pappas (Athens, Greece), K. Ntaï (Athens, Greece), E. Stagaki (Athens, Greece), A. Armaganidis (Athens, Greece), S. Orfanos (Athens, Greece). Switching to macitentan in pulmonary arterial hypertension. 3045

Member's Comments

No comment yet.

Related content which might interest you: Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Liver toxicity of sitaxentan in pulmonary arterial hypertension Source: Eur Respir J 2011; 37: 475 Year: 2011 Assessment of simvastatin treatment on pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Pulmonary arterial hypertension Source: Eur Respir Monogr 2013; 62: 70-84 Year: 2013 Pulmonary arterial hypertension Source: ISSN=ISSN 1810-6838, ISBN=, page=126 Year: 2005 Pulmonary arterial hypertension Source: Breathe 2010; 6: 377-380 Year: 2010 Pulmonary arterial hypertension Source: International Congress 2018 – State of the art session: Pulmonary vascular diseases Year: 2018 Pulmonary arterial hypertension Source: ISSN=ISSN 1810-6838, ISBN=, page=397 Year: 2007 Pulmonary arterial hypertension Source: Eur Respir Monogr 2014; 66: 232-246 Year: 2014 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Endothelium in pulmonary arterial hypertension Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015